Global sustainable infrastructure investor Actis has bought Rx Propellant, a platform focused on providing R&D labs and facilities to tenants in the life sciences and related sectors in India.
The post Actis eyes Indian life science labs demand with Rx Propellant deal first appeared on AltAssets Private Equity News.
